Accurately Predicts Risk of Progression to Cancer
Risk-aligned approach to Barrett’s esophagus management
TissueCypher is the first AI-driven precision medicine test to determine a patient’s individual risk of progression from BE to cancer. A low-risk test result enables the extension of surveillance intervals or a reduction in unnecessary medical procedures for select patients. A high-risk test result enables increased surveillance or intervention to prevent progression to EAC.
The need for TissueCypher
Clinicopathologic risk factors, such as age, sex, obesity, family history and expert pathology, have been shown to have limited ability to predict progression to esophageal cancer. TissueCypher outperforms these risk factors, and provides physicians with an actionable risk score, along with the patient's personalized five-year risk of progression.
Two non-dysplastic patients, nearly identical by pathology and clinical factors
Similar clinical risk factors and pathology based on a traditional pathology report
Using the esophageal pinch biopsy tissue, TissueCypher extracts high dimensional spatial biology data transformed by AI-driven algorithm
The healthcare provider receives risk information that is actionable for risk-aligned management decisions
How is the test run?Learn More
TissueCypher is a laboratory-developed test that analyzes tissue from standard BE pinch biopsies. The result provides a patient's individualized five-year risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
How does it work?Learn More
TissueCypher is an AI-driven test that analyzes cancer-associated protein biomarkers and spatial biology features to identify the molecular signature of progression that precede morphologic tissue changes.
Who is eligible for TissueCypher?Learn More
TissueCypher is designed for patients with recently diagnosed BE or those enrolled in a BE surveillance program. The test can be run on tissue diagnosed by pathology as non-dysplastic BE (NDBE), indefinite for dysplasia (IND) or low-grade dysplasia (LGD).
Precision risk stratification generates actionable information
TissueCypher’s performance has been validated in a series of clinical studies, which highlight its use as an independent predictor of progression that outperforms all clinicopathologic risk factors, including expert pathology. Patients scoring high risk progress at a clinically actionable rate that is higher than confirmed low-grade dysplasia.